The global pharmaceuticals manufacturing market is undergoing the most capital-intensive transformation in its modern history. The convergence of four structural forces - the GLP-1 obesity therapy revolution, an accelerating biologics mix shift, the largest biosimilar patent expiry wave on record, and the early-stage commercialisation of cell and gene therapies - is simultaneously expanding production volumes, elevating manufacturing complexity, concentrating capital expenditure among a narrow cohort of strategic investors, and reshaping the competitive geography of global pharmaceutical supply.
Global pharmaceutical manufacturing production reached an estimated $1,549 billion in 2022, expanding to $1,841 billion by 2025 at a compound annual growth rate of 5.9% over the 2022-2025 period - a moderate baseline reflecting COVID-19-related production normalisation. The forecast period from 2026 through 2031 represents a marked acceleration: global production is projected to reach $2,856 billion by 2031, implying a 7.7% CAGR from the 2025 base, the fastest sustained growth rate in the industry's modern history. GLP-1 manufacturing alone is forecast to reach approximately $180 billion annually by 2031, up from an estimated $45 billion in 2025.
Twenty-nine companies are profiled in depth, spanning integrated innovators (Eli Lilly, Novo Nordisk, Pfizer, Roche, Johnson & Johnson, and 20 others) and dedicated contract development and manufacturing organizations (Samsung Biologics, Lonza, WuXi Biologics, Catalent) - reflecting the genuine, expanding role of specialized CDMOs in global pharmaceutical production capacity.
This research report is ideal for people who wish to gain a thorough understanding of the global pharmaceutical manufacturing and supply chain landscape. Some of the intended users for this report are:
List of Exhibits
Johnson & Johnson, Eli Lilly, Merck & Co. (MSD), Pfizer, AbbVie, Roche, AstraZeneca, Novartis, Sanofi, Bristol-Myers Squibb, GSK, Novo Nordisk, Takeda, Bayer, Boehringer Ingelheim, Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Moderna, Teva Pharmaceutical Industries, Viatris, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Samsung Biologics, Lonza, WuXi Biologics, Catalent
*If Applicable.
NAVADHI is a market research company that helps global firms differentiate themselves, break market entry barriers, track their investments, develop business strategies and plan for future by providing actionable market research intelligence that helps them succeed.